Stemline Therapeutics (STML) Getting Somewhat Favorable Press Coverage, Study Shows
Headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stemline Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.508290029885 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern’s analysis:
- Stemline Therapeutics, Inc. (NASDAQ:STML) Expected to Post Q3 2017 Earnings of ($0.62) Per Share (americanbankingnews.com)
- Stemline Therapeutics, Inc. (STML) distanced 60.91% to its 52-Week Low = Technical Analysis – Voice Of Analysts (analystsbuzz.com)
- Stemline Therapeutics Reports Second Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Stemline Therapeutics Inc (NASDAQ:STML) Announces Earnings Results, Misses Expectations By $0.18 EPS (americanbankingnews.com)
- Stemline Reports Second Quarter 2017 Financial Results (biospace.com)
Shares of Stemline Therapeutics (NASDAQ:STML) opened at 7.75 on Monday. The firm’s market cap is $181.78 million. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $14.60. The company’s 50-day moving average is $9.33 and its 200 day moving average is $8.51.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.18. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. On average, analysts expect that Stemline Therapeutics will post ($2.44) earnings per share for the current fiscal year.
Several research analysts recently issued reports on the stock. ValuEngine cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. HC Wainwright set a $34.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a report on Friday, May 12th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Stemline Therapeutics currently has an average rating of “Buy” and a consensus target price of $29.17.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.